Skip to main content
Premium Trial:

Request an Annual Quote

MDS Shareholders Approve Sale of Analytical Technologies Business

NEW YORK (GenomeWeb News) – MDS shareholders have approved the sale of the firm's Analytical Technologies business to Danaher for $650 million in cash.

Shareholders representing more than 99 percent of MDS' common shares voted in favor of the sale at a meeting held Tuesday.

In early September, Danaher inked the agreement to buy MDS Analytical Technologies, plus Life Technologies' half of the mass spectrometry joint venture with MDS, for total consideration of $1.1 billion.

"Subject to the completion of sale of MDS Analytical Technologies, [MDS] currently intends to return approximately $400 million to $450 million of sale proceeds to shareholders by way of a share buyback through a Substantial Issuer Bid," James MacDonald, chairman of MDS's board of directors, said in a statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.